The conversion process is straightforward: for every one (1) American Depositary Share (ADS) currently held, shareholders will receive one (1) ordinary share of Ascendis Pharma A/S. This 1:1 exchange ratio ensures that the underlying economic interest of shareholders remains unchanged, with the primary difference being the form of their security holding.
A key aspect of this transition is the change in the CUSIP number. The current CUSIP for Ascendis Pharma's ADRs is 04351P101. Upon conversion, the new CUSIP for the ordinary shares will be K08588103. Investors should update their records accordingly to reflect this change, which is crucial for accurate portfolio management and trading.
This conversion from American Depositary Shares to ordinary shares will become effective on 20th April 2026. Shareholders should mark this date in their calendars, as it signifies the official transition point for their investments. While the effective date is some time away, it allows ample time for current ADR holders and brokers to prepare for the change.
Ascendis Pharma's decision to terminate its ADR programme and convert to ordinary shares may streamline its equity structure and could potentially affect its accessibility on various international exchanges. Historically, ADR programmes facilitate easier access for non-US investors to trade shares of foreign companies on US stock exchanges. The move to ordinary shares means investors will now hold the fundamental equity instrument of the company directly.
For any specific questions or additional information regarding this crucial corporate event, stakeholders are encouraged to contact Nasdaq Corporate Data Operations. Their dedicated support line is +1 877 308 0523. This resource can provide clarification on the mechanics of the conversion and any related procedural queries.
Furthermore, for financial institutions or individuals interested in becoming market makers for Ascendis Pharma (ASND) ordinary shares following this conversion, Nasdaq Trading Services can be contacted at +1 212 231 5100. This information is vital for ensuring liquidity and efficient trading of Ascendis Pharma's ordinary shares post-conversion.
This corporate action represents a notable development for Ascendis Pharma stakeholders. It underscores the ongoing evolution of financial instruments and the importance for investors to stay informed about changes impacting their equity holdings. UK investors, in particular, should consult with their financial advisors to understand the implications of holding ordinary shares versus ADRs within their portfolios, especially concerning custody, dividends, and voting rights.
